Commensal Bacteria as Therapy for Colorectal Cancer – Microbials 2018

This project is one of the five winners of the call 2018 «Microbials – Direct Use of Micro-Organisms». Project partners: Università della Svizzera Italiana; University of Basel and University of Zürich

Données de projet

Numéro du projet: GRS-062/18
Subside accordé: CHF 460'000
Consentement: 29.10.2018
Durée: 05.2019 - 08.2022
Champs d'activité: Microbials, seit 2016

Direction du projet

PD Dr. Giandomenica Iezzi, Head of Translational Research Lab
Università della Svizzera Italiana
Faculty of Biomedical Science
Via G. Buffi 13
6900 Lugano (Schweiz)
Giandomenica.notexisting@nodomain.comIezzi@eoc.notexisting@nodomain.comch

Description du projet

Colorectal cancer (CRC) is among the most frequent tumor types and is a leading cause of cancer-related death. Tumor infiltration by defined types of immune cells has been recently recognized to favor prolonged survival. However, immune cell infiltration spontaneously occurs in a minority of cases, below 20% . No therapy capable of enhancing immune cell recruitment into tumor tissues is currently available.
In recent studies we found that some commensal bacteria, normally present in the intestinal flora, the so-called microbiome, have the ability to stimulate tumor cells to produce chemotactic factors capable of attracting immune cells into tumor tissues. Upon analysis of the gut flora composition of human CRC samples, we have identified a group of bacterial specie which are associated with high expression of chemokines, high densities of tumor infiltrating cells, and prolonged patients’ survival.
These findings suggest the potential therapeutic administration of identified bacteria to increase CRC infiltration by immune cells, thereby improving clinical outcome. With the present project, we aimed at selecting the most effective bacterial species and combinations for subsequent clinical application.

Quelles sont les particularités de ce projet?

This the first study evaluating the potential therapeutic application of bacterial species found to be associated with favorable clinical outcome in patients with CRC. The newly developed microbiome-based treatment might represent a valid innovative therapy for patients suffering from CRC, estimated, based on published data, as >1 M patients per year worldwide. Enhancement of immune infiltration in CRC upon bacteria-based therapy is expected to increase recurrence free and overall survival in early stage CRCs. Moreover, in advanced CRC cases, it might increase response rates to standard chemotherapies or emerging immunotherapies.

Etat/résultats intermédiaires

The project is being implemented within the newly established Translational Research group of the Department of Surgery, of the Ente Ospedaliero Cantonale, strategically embedded within the Institute of Research of Biomedicine, in close contact with other groups of prominent oncologists and immunologists. In the first two years of funding, we have investigated the capacity of individual bacterial species to induce in tumor cells the expression of chemokines recruiting immune cells into tumor tissues. We have identified a group of five bacterial species effectively inducing in tumor cells upregulation of chemokine genes in vitro. We have recently started to test the ability of these bacteria to promote recruitment of immune cells into tumors, in an experimental CRC model. Preliminary results indicate that administration of at least one of the tested bacterial species leads to enhanced intra-tumoral recruitment of immune cells and reduced tumor development. We next intend to assess whether the increased immune infiltration promoted by bacteria administration may result in enhanced effectiveness immunotherapies based on immunological checkpoint inhibitors.

Publications

Droeser RA, Iezzi G. IL-22-mediates Cross-talk between Tumor Cells and Immune Cells Associated with Favorable Prognosis in Human Colorectal Cancer. J Cell Immunol. 2021;3:118-121.
Tosti N, Cremonesi E, Governa V, Basso C, Kancherla V, Coto-Llerena M, Amicarella F, Weixler B, Däster S, Sconocchia G, Majno PE, Christoforidis D, Tornillo L, Terracciano L, Ng CKY, Piscuoglio S, von Flüe M, Spagnoli G, Eppenberger-Castori S, Iezzi G, Droeser RA. Infiltration by IL22-Producing T Cells Promotes Neutrophil Recruitment and Predicts Favorable Clinical Outcome in Human Colorectal Cancer. Cancer Immunol Res. 2020 Aug 24. doi: 10.1158/2326-6066.CIR-19-0934.
Manfredonia C, Muraro MG, Hirt C, Mele V, Governa V, Papadimitropoulos A, Däster S, Soysal SD, Droeser RA, Mechera R, Oertli D, Rosso R, Bolli M, Zettl A, Terracciano LM, Spagnoli GC, Martin I, Iezzi G. Maintenance of Primary Human Colorectal Cancer Microenvironment Using a Perfusion Bioreactor-Based 3D Culture System. Adv Biosyst. 2019 Apr;3(4):e1800300. doi: 10.1002/adbi.201800300.
Iezzi G, Cremonesi E, Majno PE. Pro-tumoral role of gut bacteria: sabotaging immune cell recruitment. Ann Transl Med. 2019 Feb;7(3):59. doi: 10.21037/atm.2018.12.56.
Cremonesi E, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, Trella E, Galati-Fournier V, Oertli D, Däster SR, Droeser RA, Weixler B, Bolli M, Rosso R, Nitsche U, Khanna N, Egli A, Keck S, Slotta-Huspenina J, Terracciano LM, Zajac P, Spagnoli GC, Eppenberger-Castori S, Janssen KP, Borsig L, Iezzi G. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018 Nov;67(11):1984-1994. doi: 10.1136/gutjnl-2016-313498. Epub 2018 Feb 6. Artikel on Youtube

Revue de presse

I batteri dell’intestino? Possono aiutare contro i tumori, Report on IBSA website, 15.05.2020
Passa dall’EOC la ricerca di nuove terapie per il tumore del colon, EOC Press release, 24.04.2019
Tumore al colon e flora intestinale, la ricerca passa dal Ticino, Report in La Regione, 24.04.2019

Liens

USI, Faculty of Biomedical Sciences
Ente Ospedaliero Cantonale

Personnes participant au projet

PD Dr. Giandomenica Iezzi Head of Translational Research Lab, Università della Svizzera Italiana, Department of Surgery, Ente Ospedaliero Cantonale and Faculty of Biomedical Science
Prof. Majno-Hurst, Head of the Department of Surgery, Ente Ospedaliero Cantonale Lugano and Chair of Surgery of the Università Svizzera Italiana (USI)
Prof. Dimitri Christoforidis, Deputy Head of the Department of Surgery Ente Ospedaliero Cantonale Lugano, specialized in colorectal surgery

Dernière mise à jour de cette présentation du projet 22.09.2022

PORTEFEUILLE

Présentation des projets sur le site web

Champs d'activité

Année